Innate Pharma (IPHA) Retained Earnings (2017 - 2025)

Innate Pharma (IPHA) has disclosed Retained Earnings for 8 consecutive years, with $28852.1 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Retained Earnings fell 94.58% year-over-year to $28852.1, compared with a TTM value of $28852.1 through Dec 2024, down 94.58%, and an annual FY2024 reading of $29223.1, down 94.54% over the prior year.
  • Retained Earnings was $28852.1 for Q4 2024 at Innate Pharma, down from $532590.3 in the prior quarter.
  • Across five years, Retained Earnings topped out at $835582.6 in Q4 2022 and bottomed at $28852.1 in Q4 2024.
  • Average Retained Earnings over 5 years is $468387.7, with a median of $521650.8 recorded in 2021.
  • The sharpest move saw Retained Earnings skyrocketed 181.01% in 2020, then tumbled 94.58% in 2024.
  • Year by year, Retained Earnings stood at $423262.9 in 2020, then rose by 23.25% to $521650.8 in 2021, then surged by 60.18% to $835582.6 in 2022, then plummeted by 36.26% to $532590.3 in 2023, then crashed by 94.58% to $28852.1 in 2024.
  • Business Quant data shows Retained Earnings for IPHA at $28852.1 in Q4 2024, $532590.3 in Q4 2023, and $835582.6 in Q4 2022.